| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Microbiology and Immunology, The Jefferson Cancer Institute [D. K. M., M. H-M., G. R., G. G., A. J. W.] and Department of Neurology [P. W. Z.], Thomas Jefferson University, Philadelphia, Pennsylvania 19107; Department of Medical Oncology, The Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [A. K. G.]; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [J. A. B.]; and Department of Neurosurgery, New York University Medical Center, New York, New York 10016 [R. L. H.]
The epidermal growth factor receptor has received much interest as a target for various antineoplastic agents, but a complication is that many normal tissues also express this receptor. We have previously identified in human glial tumors an 801-bp in-frame deletion within the epidermal growth factor receptor gene that created a novel epitope at the junction. By using Western blot assays with a mutant-specific antibody as a rapid and sensitive means for detecting this alteration in primary human tumors, it was found that 57% (26 of 46) of high-grade and 86% (6 of 7) of low-grade glial tumors, but not normal brain, express this protein. This altered receptor was also present in 66% (4 of 6) of pediatric gliomas and 86% (6 of 7) of medulloblastomas, 78% (21 of 27) of breast carcinomas, and 73% (24 of 32) of ovarian carcinomas. The fact that this receptor is frequently found in tumors but not in normal tissue makes it an attractive candidate for various antitumor strategies.
1 This work was supported by CA-51093, NS-31102, and the Ronald McDonald Children's Charities Foundation.
2 These two authors contributed equally to this work.
3 To whom correspondence should be addressed, at Jefferson Cancer Institute, BLSB 1002, 233 South 10th Street, Philadelphia, PA 19107.
Received 9/20/95. Accepted 10/19/95.
This article has been cited by other articles:
|
|
 |
|
  S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Steffensen, M. Waldstrom, D. A. Olsen, T. Corydon, K. A. Lorentzen, H. J. Knudsen, U. Jeppesen, I. Brandslund, and A. Jakobsen Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors Clin. Cancer Res., June 1, 2008; 14(11): 3278 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Emanuel, T. V. Hughes, M. Adams, C. A. Rugg, A. Fuentes-Pesquera, P. J. Connolly, N. Pandey, S. Moreno-Mazza, J. Butler, V. Borowski, et al. Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors Mol. Pharmacol., February 1, 2008; 73(2): 338 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Choi and J.N. Myers Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy J. Dent. Res., January 1, 2008; 87(1): 14 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Grandal, R. Zandi, M. W. Pedersen, B. M. Willumsen, B. van Deurs, and H. S. Poulsen EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes Carcinogenesis, July 1, 2007; 28(7): 1408 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Vikis, M. Sato, M. James, D. Wang, Y. Wang, M. Wang, D. Jia, Y. Liu, J. E. Bailey-Wilson, C. I. Amos, et al. EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity Cancer Res., May 15, 2007; 67(10): 4665 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Larsen, M. W. Pedersen, M.-T. Stockhausen, M. V. Grandal, B. v. Deurs, and H. S. Poulsen Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor-Induced Cancer Cell Motility Mol. Cancer Res., March 1, 2007; 5(3): 283 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Gan, F. Walker, A. W. Burgess, A. Rigopoulos, A. M. Scott, and T. G. Johns The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers: IMPLICATIONS FOR COMBINATION THERAPY WITH MONOCLONAL ANTIBODY 806 J. Biol. Chem., February 2, 2007; 282(5): 2840 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Blehm, P. E. Spiess, J. E. Bondaruk, M. E. Dujka, G. J. Villares, Y.-j. Zhao, O. Bogler, K. D. Aldape, H. B. Grossman, L. Adam, et al. Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy Clin. Cancer Res., August 1, 2006; 12(15): 4671 - 4677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. El-Deiry, C. C. Sigman, and G. J. Kelloff Imaging and Oncologic Drug Development J. Clin. Oncol., July 10, 2006; 24(20): 3261 - 3273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors PNAS, May 16, 2006; 103(20): 7817 - 7822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Sonnweber, M Dlaska, S Skvortsov, S Dirnhofer, T Schmid, and W Hilbe High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J. Clin. Pathol., March 1, 2006; 59(3): 255 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Prados, K. R. Lamborn, S. Chang, E. Burton, N. Butowski, M. Malec, A. Kapadia, J. Rabbitt, M. S. Page, A. Fedoroff, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro-oncol, January 1, 2006; 8(1): 67 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ning, R. Zeineldin, Y. Liu, M. Rosenberg, M. S. Stack, and L. G. Hudson Down-regulation of Integrin {alpha}2 Surface Expression by Mutant Epidermal Growth Factor Receptor (EGFRvIII) Induces Aberrant Cell Spreading and Focal Adhesion Formation Cancer Res., October 15, 2005; 65(20): 9280 - 9286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-T. Zhang, L.-Y. Li, X.-L. Mu, Q.-C. Cui, X.-Y. Chang, W. Song, S.-L. Wang, M.-Z. Wang, W. Zhong, and L. Zhang The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer Ann. Onc., August 1, 2005; 16(8): 1334 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Schilder, M. W. Sill, X. Chen, K. M. Darcy, S. L. Decesare, G. Lewandowski, R. B. Lee, C. A. Arciero, H. Wu, and A. K. Godwin Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study Clin. Cancer Res., August 1, 2005; 11(15): 5539 - 5548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Solit, Y. She, J. Lobo, M. G. Kris, H. I. Scher, N. Rosen, and F. M. Sirotnak Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel Clin. Cancer Res., March 1, 2005; 11(5): 1983 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Carter, L. Smith, and M. Ryan Identification and validation of cell surface antigens for antibody targeting in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Matheson, J. P. McNamee, T. Wang, M. A. Alaoui-Jamali, A. M. Tari, and B. J. Jean-Claude The Combi-Targeting Concept: Dissection of the Binary Mechanism of Action of the Combi-Triazene SMA41 in Vitro and Antitumor Activity in Vivo J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan and D. M. O'Rourke SHP-2-Dependent Mitogen-Activated Protein Kinase Activation Regulates EGFRvIII but not Wild-Type Epidermal Growth Factor Receptor Phosphorylation and Glioblastoma Cell Survival Cancer Res., November 15, 2004; 64(22): 8292 - 8298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al. Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R) J. Immunol., November 15, 2004; 173(10): 6472 - 6480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lammering, T. H. Hewit, M. Holmes, K. Valerie, W. Hawkins, P.-S. Lin, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity Clin. Cancer Res., October 1, 2004; 10(19): 6732 - 6743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano Pharmacological background of EGFR targeting Ann. Onc., July 1, 2004; 15(7): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Scagliotti, G. Selvaggi, S. Novello, and F. R. Hirsch The Biology of Epidermal Growth Factor Receptor in Lung Cancer Clin. Cancer Res., June 15, 2004; 10(12): 4227S - 4232S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Learn, T. L. Hartzell, C. J. Wikstrand, G. E. Archer, J. N. Rich, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme Clin. Cancer Res., May 1, 2004; 10(9): 3216 - 3224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shinojima, K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. Makino, H. Saya, H. Hirano, J.-i. Kuratsu, et al. Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme Cancer Res., October 15, 2003; 63(20): 6962 - 6970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr, M. V. Di Maria, R. Veve, R. M. Bremnes, A. E. Baron, C. Zeng, and W. A. Franklin Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis J. Clin. Oncol., October 15, 2003; 21(20): 3798 - 3807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn and J. Baselga Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Grunwald and M. Hidalgo Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Tidow, A. Boecker, H. Schmidt, K. Agelopoulos, W. Boecker, H. Buerger, and B. Brandt Distinct Amplification of an Untranslated Regulatory Sequence in the egfr Gene Contributes to Early Steps in Breast Cancer Development Cancer Res., March 15, 2003; 63(6): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lavictoire, D. A. E. Parolin, A. C. Klimowicz, J. F. Kelly, and I. A. J. Lorimer Interaction of Hsp90 with the Nascent Form of the Mutant Epidermal Growth Factor Receptor EGFRvIII J. Biol. Chem., February 7, 2003; 278(7): 5292 - 5299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Jungbluth, E. Stockert, H. J. S. Huang, V. P. Collins, K. Coplan, K. Iversen, D. Kolb, T. J. Johns, A. M. Scott, W. J. Gullick, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor PNAS, January 21, 2003; 100(2): 639 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Arteaga Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression? Oncologist, August 15, 2002; 7(90004): 31 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Penington, I. Bryant, and D. J. Riese II Constitutively Active ErbB4 and ErbB2 Mutants Exhibit Distinct Biological Activities Cell Growth Differ., June 1, 2002; 13(6): 247 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Cavenee Genetics and new approaches to cancer therapy Carcinogenesis, May 1, 2002; 23(5): 683 - 686. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Senger, C. Tudan, M.-C. Guiot, I. E. Mazzoni, G. Molenkamp, R. LeBlanc, J. Antel, A. Olivier, G. J. Snipes, and D. R. Kaplan Suppression of Rac Activity Induces Apoptosis of Human Glioma Cells but not Normal Human Astrocytes Cancer Res., April 1, 2002; 62(7): 2131 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Molina, R. Saez, E. E. Ramsey, M.-J. Garcia-Barchino, F. Rojo, A. J. Evans, J. Albanell, E. J. Keenan, A. Lluch, J. Garcia-Conde, et al. NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer Clin. Cancer Res., February 1, 2002; 8(2): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Arteaga The Epidermal Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia J. Clin. Oncol., September 15, 2001; 19(90001): 32s - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mishima, T. G. Johns, R. B. Luwor, A. M. Scott, E. Stockert, A. A. Jungbluth, X.-D. Ji, P. Suvarna, J. R. Voland, L. J. Old, et al. Growth Suppression of Intracranial Xenografted Glioblastomas Overexpressing Mutant Epidermal Growth Factor Receptors by Systemic Administration of Monoclonal Antibody (mAb) 806, a Novel Monoclonal Antibody Directed to the Receptor Cancer Res., July 1, 2001; 61(14): 5349 - 5354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Luwor, T. G. Johns, C. Murone, H-J. S. Huang, W. K. Cavenee, G. Ritter, L. J. Old, A. W. Burgess, and A. M. Scott Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR Cancer Res., July 1, 2001; 61(14): 5355 - 5361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lammering, T. H. Hewit, W. T. Hawkins, J. N. Contessa, D. B. Reardon, P.-S. Lin, K. Valerie, P. Dent, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization J Natl Cancer Inst, June 20, 2001; 93(12): 921 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lammering, K. Valerie, P.-S. Lin, R. B. Mikkelsen, J. N. Contessa, J. P. Feden, J. Farnsworth, P. Dent, and R. K. Schmidt-Ullrich Radiosensitization of Malignant Glioma Cells through Overexpression of Dominant-Negative Epidermal Growth Factor Receptor Clin. Cancer Res., March 1, 2001; 7(3): 682 - 690. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Snitkovsky, T. M. J. Niederman, B. S. Carter, R. C. Mulligan, and J. A. T. Young A TVA-Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor J. Virol., October 15, 2000; 74(20): 9540 - 9545. [Abstract] [Full Text]
|
|
|
|
|
|
C. F. Foulon, C. J. Reist, D. D. Bigner, and M. R. Zalutsky Radioiodination via D-Amino Acid Peptide Enhances Cellular Retention and Tumor Xenograft Targeting of an Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody Cancer Res., August 1, 2000; 60(16): 4453 - 4460. [Abstract] [Full Text]
|
|
|
|
|
|
R. Beers, P. Chowdhury, D. Bigner, and I. Pastan Immunotoxins with Increased Activity against Epidermal Growth Factor Receptor vIII-expressing Cells Produced by Antibody Phage Display Clin. Cancer Res., July 1, 2000; 6(7): 2835 - 2843. [Abstract] [Full Text]
|
|
|
|
|
|
C. K. Tang, X.-Q. Gong, D. K. Moscatello, A. J. Wong, and M. E. Lippman Epidermal Growth Factor Receptor vIII Enhances Tumorigenicity in Human Breast Cancer Cancer Res., June 1, 2000; 60(11): 3081 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-T. Kuan, C. J. Reist, C. F. Foulon, I. A. J. Lorimer, G. Archer, C. N. Pegram, I. Pastan, M. R. Zalutsky, and D. D. Bigner 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts Clin. Cancer Res., June 1, 1999; 5(6): 1539 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Biegel Cytogenetics and molecular genetics of childhood brain tumors Neuro-oncol, April 1, 1999; 1(2): 139 - 151. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Sampson THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif. Neuro-oncol, January 1, 1999; 1(1): 33 - 42. [PDF]
|
|
|
|
 |
|
 V. B. Thogersen, P. Bross, N. Gregersen, and E. Nexo Quantitative Analysis of the Human Epidermal Growth Factor Receptor Messenger RNA Using Reverse Transcription-PCR: A Methodological Study of Imprecision Clin. Chem., June 1, 1998; 44(6): 1344 - 1346. [Full Text] [PDF]
|
|
|
|
|
|
M. Nagane, A. Levitzki, A. Gazit, W. K. Cavenee, and H.-J. S. Huang Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases PNAS, May 12, 1998; 95(10): 5724 - 5729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Antonyak, D. K. Moscatello, and A. J. Wong Constitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor Receptor J. Biol. Chem., January 30, 1998; 273(5): 2817 - 2822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Moscatello, M. Holgado-Madruga, D. R. Emlet, R. B. Montgomery, and A. J. Wong Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor J. Biol. Chem., January 2, 1998; 273(1): 200 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Worthylake and H. S. Wiley Structural Aspects of the Epidermal Growth Factor Receptor Required for Transmodulation of erbB-2/neu J. Biol. Chem., March 28, 1997; 272(13): 8594 - 8601. [Abstract] [Full Text] [PDF]
|
|
|
|
